Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.
Crosignani S, et al. Among authors: arrighi jf.
J Med Chem. 2008 Apr 10;51(7):2227-43. doi: 10.1021/jm701383e. Epub 2008 Mar 5.
J Med Chem. 2008.
PMID: 18318469